Cancers (solid tumours)

Alecensa (alectinib)

This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.

Alecensa (Alectinib) capsule) is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung

cancer (NSCLC) as detected by an FDA-approved test. It is also now approved for adjuvant treatment (after surgery) in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node-positive) as detected by an FDA-approved test.

In case of any adverse events or safety queries, please contact:

If you have a scientific query related to one of Roche's products, please contact:

M-PK-00001196

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.

ContactLocationslinkedinfacebooktwitterinstagramyoutubeAbout RochePharma solutionsRoche careersPrivacy StatementLegal Statement